BioLife Solutions, Inc. — Earnings

Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR

Next earnings (estimated): Wed, April 1, 2026 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31$19M
2025-09-30$28M↑+31.2%$621K↑+136.5%-0.3%
2025-06-30$25M↑+28.9%$-16M↑+23.6%-65.5%
2025-03-31$24M↑+29.9%$-448K↑+95.6%-5.1%
2024-12-31
2024-09-30$21M↓-9.3%$-2M↑+94.2%-2.0%
2024-06-30$20M↓-32.6%$-21M↓-103.1%-6.6%
2024-03-31$18M↓-51.1%$-10M↑+25.5%-17.9%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q4)

Revenue
$19M
Net Income
$46M

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 64 quarters

margin trajectory tells the operating-leverage story
Gross Margin
259.4%
Operating Margin↑+1.6pts
-0.3%
Net Margin↑+10.2pts
2.2%

Go deeper